The evolution of adjuvant therapy in the treatment of early-stage colon cancer

Clinical Colorectal Cancer

Volumn 10, Issue 4, 2011, Pages 218-226

  De Gramont, Aimery ^a,b,c   De Gramont, Armand ^a   Chibaudel, Benoist ^a   Larsen, Annette K ^b   Tournigand, Christophe ^a,b   Andr, Thierry ^a,b,c  

^a Assistance Publique des Hpitaux de Paris   (France)

^b Institut National de la Sant et de la Recherche Mdicale   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Adjuvant chemotherapy; Bevacizumab; Biomarkers; Cetuximab; Elderly; Fluoropyrimidines; Oxaliplatin; Phase III; Stage II colon cancer; Stage III colon cancer

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EDRECOLOMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; SEMUSTINE; TEGAFUR; THIOTEPA; URACIL; VINCRISTINE;

ARTERIAL ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MECHANISM; ELDERLY CARE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; PROGNOSIS; RASH; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84855963151     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.10.001     Document Type: Review

References (97)

1. World Estimated Cancer Incidence Both Sexes, Age [Undefined-Undefined] [Web site] http://globocan.iarc.fr/summary-table-pop.asp?selection= 219900&title=World&sex=0&type=0&window=1&sort=0&submit= %A0Execute%A0 Accessed: October 22, 2011
2. C. Dukes The classification of cancer of the rectum J Pathol Bacteriol 35 1932 323 332
3. C.G. Moertel Large bowel J.F. Holland, E. Frei III Cancer Medicine 1973 Lea & Febiger Philadelphia 1597 1627
4. C. Heidelberger, N.K. Chauduri, and P. Danneberg Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
5. J.C. Nystrom, J.R. Bateman, and J. Weiner Adjuvant treatment of colorectal cancera review West J Med 126 1977 95-10
6. C.G. Moertel Chemotherapy of gastrointestinal cancer N Engl J Med 299 1978 1049 1052
7. D. Machover, E. Goldschmidt, and P. Chollet Treatment of advanced colorectal and gastric adenocarcinomas with 5-flurouracil and high-dose folinic acid J Clin Oncol 4 1986 685 696 (Pubitemid 16114715)
8. N. Petrelli, L. Herrera, and Y. Rustum A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma J Clin Oncol 5 1987 1559 1565 (Pubitemid 18010132)
9. M.A. Poon, M.J. O'Connell, and C.G. Moertel Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma J Clin Oncol 7 1989 1407 1418 (Pubitemid 19245110)
10. A. de Gramont, M. Krulik, and J. Cady High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer Eur J Cancer Oncol 24 1988 1499 1503
11. Gastrointestinal Tumor Study Group Adjuvant therapy of colon cancer Results of a prospective randomized trial N Engl J Med 310 1984 737 743
12. Fluorouracil as an adjuvant to colorectal cancer surgery the breakthrough that never was JAMA 236 1976 1935 1936
13. J.A. Laurie, C.G. Moertel, and T.R. Fleming Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil The North Central Cancer Treatment Group and the Mayo Clinic J Clin Oncol 7 1989 1447 1456 (Pubitemid 19245114)
14. N. Wolmark, B. Fisher, and H. Rockette Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01 J Natl Cancer Inst 80 1988 30 33
15. M. Buyse, A. Zeleniuch-Jacquotte, and T.C. Chalmers Adjuvant therapy of colorectal cancer Why we still don't know JAMA 259 1988 3571 3578
16. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322 1990 352 358 (Pubitemid 20042739)
17. A.H. Rossof, T.R. Philpot, and R.S. Bunch The high cost of levamisole for human N Engl J Med 324 1991 701 702
18. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report Ann Intern Med 122 1995 321 326
19. N. Wolmark, H. Rockette, and E. Mamounas Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project C-04 J Clin Oncol 17 1999 3553 3559 (Pubitemid 29517927)
20. D.G. Haller, P.J. Catalano, and J.S. Macdonald Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089 J Clin Oncol 23 2005 8671 8678 (Pubitemid 46211510)
21. T. Andr, P. Colin, and C. Louvet A semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial J Clin Oncol 21 2003 2896 2903 (Pubitemid 46621839)
22. T. Andr, E. Quinaux, and C. Louvet Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1 J Clin Oncol 20 2007 3732 3738 (Pubitemid 47372615)
23. N. Wolmark, R. Bryan, and J. Grem Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project. Protocol C-05 J Natl Cancer Inst 90 1998 1810 1816 (Pubitemid 28559893)
24. J.A. Cornelis, C.J.A. Punt, and A. Nagy Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study Lancet 360 2002 671 677 (Pubitemid 35232335)
25. I. Popov, A. Carrato, and A. Sobrero Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) Eur J Cancer 44 2008 2204 2211
26. D.J. Sargent, R.M. Goldberg, and S.D. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 2001 1091 1097
27. R. Gray, J. Barnwell, and C. McConkey Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 370 2007 2020 2029
28. T. Andr, C. Boni, and L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators N Engl J Med 350 2004 2343 2351
29. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204 (Pubitemid 46954643)
30. D.G. Haller, J. Tabernero, and J. Maroun Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer J Clin Oncol 29 2011 1465 1471
31. T. Andr, C. Boni, and M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial J Clin Oncol 27 2009 3109 3116
32. D.J. Sargent, H.S. Wieand, and D.G. Haller Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 23 2005 8664 8670 (Pubitemid 46211509)
33. C. Twelves, A. Wong, and M.P. Nowacki Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696 2704 (Pubitemid 41007824)
34. J. Sakamoto, Y. Ohashi, and C. Hamada Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials J Clin Oncol 22 2004 484 492 (Pubitemid 41079778)
35. B.C. Lembersky, H.S. Wieand, and N.J. Petrelli Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06 J Clin Oncol 24 2006 2059 2064 (Pubitemid 46622115)
36. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
37. L.B. Saltz, D. Niedzwiecki, and D. Hollis Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 J Clin Oncol 25 2007 3456 3461 (Pubitemid 47310883)
38. M. Ychou, W. Hohenberger, and S. Thezenas A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol 20 2009 1964 1970
39. E. Van Cutsem, R. Labianca, and G. Bodoky Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 J Clin Oncol 27 2009 3117 3125
40. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
41. F.F. Kabbinavar, J. Schulz, and M. McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer Results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
42. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
43. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
44. J. Folkman, K. Watson, and D. Ingber Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 61 (Pubitemid 19115892)
45. C. Allegra, G. Yothers, and M. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
46. C.J. Allegra, G. Yothers, and M.J. O'Connell Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 J Clin Oncol 29 2011 11 16
47. C. Allegra Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer [abstract] J Clin Oncol 29 suppl 2011 abstract 3508
48. S. Loges, M. Mazzone, and P. Hohensinner Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 2009 167 170
49. J.M. Ebos, C.R. Lee, and W. Cruz-Munoz Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
50. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
51. P. Hoff, S. Clarke, and D. Cunnigham A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial Eur J Cancer Supplements 7 2009 324
52. T. Andr A multinational, randomized phase III study of bevacizumab with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer: subgroup analyses from the AVANT trial J Clin Oncol 29 suppl 2011 abstract 3509
53. A. Livre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379 (Pubitemid 351171687)
54. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
55. C. Bokemeyer, I. Bondarenko, and J. Hartmann Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2008 663 671
56. T.S. Maughan, R.A. Adams, and C.G. Smith Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
57. S.R. Alberts, D.J. Sargent, and T.C. Smyrrk Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial NO147 J Clin Oncol 28 suppl 18S 2010 959s
58. R.M. Goldberg, D.J. Sargent, and N. Thibodeau Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG intergroup phase III trial NO147 J Clin Oncol 28 suppl 15S 2010 262s
59. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
60. A. de Gramont, and E. Van Cutsem Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer Oncology 69 suppl 3 2005 46 56 (Pubitemid 41680952)
61. W. Cacheux, T. Boisserie, and L. Staudacher Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery Ann Oncol 19 2008 1659 1661
62. G.N. Naumov, J.L. Townson, and I.C. MacDonald Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases Breast Cancer Res Treat 82 2003 199 206 (Pubitemid 37521976)
63. N. Almog Molecular mechanisms underlying tumor dormancy Cancer Lett 294 2010 139 146
64. D.L. Wheeler, S. Huang, and T.J. Kruser Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 2008 3944 3956 (Pubitemid 351913636)
65. A. Jain, E. Penuel, and S. Mink HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation Cancer Res 70 2010 1989 1999
66. Z.A. Rasheed, and E.H. Rubin Mechanisms of resistance to topoisomerase I-targeting drugs Oncogene 22 2003 7296 7304 (Pubitemid 37487161)
67. F.A. Sinicrope, R.L. Rego, and N.R. Foster Proapoptotic bad and bid protein expression predict survival in stage II and III colon cancers Clin Cancer Res 14 2008 4128 4133
68. UN Data. Life expectancy at age x [Web site] http://data.un.org/Data. aspx?d=GenderStat&f=inID%3A36 Accessed: October 22, 2011
69. R.M. Goldberg, I. Tabah-Fisch, and H. Bleiberg Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Clin Oncol 24 2006 4085 4091 (Pubitemid 46622283)
70. N.A. Jackson McCleary, J. Meyerhardt, and E. Green Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients with stage II/III colon cancer: findings from the ACCENT database J Clin Oncol 27 15S 2009 4010
71. G. Yothers, M.J. O'Connell, and C.J. Allegra Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 including survival and subset analyses J Clin Oncol 29 2011 3768 3774
72. G.A. Yothers The efficacy of oxaliplatin when added to 5-fluorouracil/leucovorin in stage II colon cancer [abstract] J Clin Oncol 29 suppl 2011 a3507
73. C. Tournigand, and A. de Gramont Chemotherapy: is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol 8 2011 574 576
74. American Joint Committee on Cancer AJCC Cancer Staging Manual 7th edition 2010 Springer New York, NY 978-0-387-88440-0
75. J.B. Bachet, P. Laurent-Puig, and A. de Gramont Microsatellite status and adjuvant chemotherapy in patients with stage II colon cancer Curr Colorectal Cancer Rep 6 2010 148 157
76. P.M. Johnson, G.A. Porter, and R. Ricciardi Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer J Clin Oncol 24 2006 3570 3575 (Pubitemid 46630528)
77. A.C. Berger, E.R. Sigurdson, and T. LeVoyer Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes J Clin Oncol 23 2005 8706 8712 (Pubitemid 46211514)
78. L.L. Gunderson, J.M. Jessup, and D.J. Sargent Revised TN categorization for colon cancer based on national survival outcomes data J Clin Oncol 28 2010 264 271
79. D.J. Sargent, S. Marsoni, and G. Monges Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol 28 2010 3219 3226
80. M.J. O'Connell, I. Lavery, and G. Yothers Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin J Clin Oncol 28 2010 3937 3944
81. A.D. Roth, S. Tejpar, and P. Yan Molecular markers in colon cancer have a stage specific prognostic value Results of the translational study on the PETACC 3 - EORTC 40993 -SAKK 60-00 trial J Clin Oncol 27 suppl 15S 2009 4002
82. A.D. Roth, S. Tejpar, and M. Delorenzi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial J Clin Oncol 28 2010 466 474
83. T. Watanabe, T.T. Wu, and P.J. Catalano Molecular predictors of survival after adjuvant chemotherapy for colon cancer N Engl J Med 344 2001 1196 1206 (Pubitemid 32319494)
84. A. Zaanan, P. Cuilliere-Dartigues, and A. Guilloux Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin Ann Oncol 21 2010 772 780
85. P.L. Pallante, L. Terracciano, and V. Carafa The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients Eur J Cancer 46 2010 2304 2313
86. D. Kerr, R. Gray, and P. Quirke A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study J Clin Oncol 27 15S 2009 4000
87. M. Buyse, D.J. Sargent, and A. Grothey Biomarkers and surrogate end points: the challenge of statistical validation Nat Rev Clin Oncol 7 2010 309 317
88. N. Love, C. Bylund, and N.J. Meropol How well do we communicate with our patients? A survey of patients who received adjuvant chemotherapy for colorectal cancer J Clin Oncol 25 2007 168s
89. P. Blinman, V. Duric, and A.K. Nowak Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer 46 2010 1800 1807
90. T. Watanabe Ongoing colorectal cancer adjuvant trials in Japan Curr Colorectal Cancer Rep 6 2010 168 174
91. I. Amit, R. Wides, and Y. Yarden Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy Mol Syst Biol 3 2007 151
92. M. Brackstone, J.L. Townson, and A.F. Chambers Tumour dormancy in breast cancer: an update Breast Cancer Res 9 2007 208
93. K.S. Albain, W.E. Barlow, and P.M. Ravdin Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 2055 2063
94. G. Mariani, A. Fasolo, and E. De Benedictis Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer Nat Clin Pract Oncol 6 2009 93 104
95. L. Gianni, U. Dafni, and R.D. Gelber Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 2011 236 244
96. D.J. Sargent, S. Patiyil, and G. Yothers End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group J Clin Oncol 25 2007 4569 4574 (Pubitemid 350035314)
97. D. Sargent, Q. Shi, and G. Yothers Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Adjuvant Colon Cancer End-points (ACCENT) Group Eur J Cancer 47 2011 990 996